BRIDGEWATER, N.J. (AP) — Merck & Co. CEO Kenneth Frazier tells company shareholders that this year and next will be difficult.
Speaking at the company's annual meeting, Frazier noted the drugmaker's top-selling product, asthma and allergy drug Singulair, gets U.S. generic competition soon. That will sharply reduce revenue from Singulair, which brought in $5.5 billion last year.
He also cited an uncertain global economy.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.